What it's for (Indications)
- Trifluoperazine is primarily indicated for the management of manifestations of psychotic disorders, particularly schizophrenia.
- It is effective in ameliorating both positive and negative symptoms of schizophrenia, though its impact is more pronounced on the positive symptoms such as hallucinations, delusions, and disorganized thought processes.
- Additionally, trifluoperazine may be used for the short-term treatment of non-psychotic anxiety, typically reserved for severe cases where standard anxiolytics are ineffective or contraindicated, and often as an adjunct therapy.
- Its role in anxiety management is generally limited due to its side effect profile, which includes significant extrapyramidal symptoms.
- Careful patient selection and dosage titration are crucial for both indications to ensure therapeutic benefit while minimizing potential risks.
- Its use should be under strict medical supervision due to its potency and potential for severe adverse effects.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For the management of schizophrenia, oral trifluoperazine typically initiates at a dose of 2 mg to 5 mg administered twice daily. The dosage can be gradually increased, generally by 2 mg increments, at intervals of several days, depending on patient response and tolerability. The usual maximum recommended dosage for outpatients is typically 40 mg per day, while hospitalized patients with more severe symptoms may require up to 60 mg to 80 mg per day under close medical supervision. Intramuscular administration is available for acute control of severe symptoms, typically 1 mg to 2 mg every 4 to 6 hours as needed, with a maximum daily dose of 10 mg. For short-term treatment of non-psychotic anxiety, the usual starting oral dose is 1 mg to 2 mg administered twice daily, with a maximum daily dose generally not exceeding 6 mg. Dosage adjustments must always be individualized based on clinical response, tolerability, and the severity of the condition, and closely monitored to balance therapeutic efficacy with the risk of adverse effects. |
Safety & Warnings
Common Side Effects
- Trifluoperazine is associated with a wide range of potential side effects, reflecting its broad pharmacological activity.
- A significant concern is the high incidence of extrapyramidal symptoms (EPS), which can manifest as acute dystonia (sustained muscle contractions), akathisia (inner restlessness and urge to move), pseudoparkinsonism (tremor, rigidity, bradykinesia), and potentially irreversible tardive dyskinesia (TD), characterized by involuntary, repetitive movements, particularly of the face, tongue, and extremities.
- Other common adverse effects include sedation, drowsiness, orthostatic hypotension, blurred vision, dry mouth, constipation, urinary retention, and nasal congestion, primarily due to its anticholinergic and alpha-adrenergic blocking properties.
- Endocrine disturbances like hyperprolactinemia, leading to galactorrhea, amenorrhea, or gynecomastia, are also possible.
- Rare but severe adverse events include Neuroleptic Malignant Syndrome (NMS), a life-threatening idiosyncratic reaction characterized by fever, severe muscle rigidity, altered mental status, and autonomic instability, as well as agranulocytosis and severe dermatological reactions.
- Cardiovascular effects, including QT prolongation, warrant caution, especially in patients with pre-existing cardiac conditions.
- Weight gain and metabolic changes can also occur.
Serious Warnings
- Black Box Warning: **WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis.** Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs such as trifluoperazine may increase mortality in elderly patients with dementia-related psychosis. Trifluoperazine is not approved for the treatment of patients with dementia-related psychosis. Healthcare providers should counsel patients and caregivers about this serious risk before initiating treatment with trifluoperazine in elderly patients. This warning underscores the critical importance of careful patient selection and thorough risk-benefit assessment for this vulnerable population.
- Trifluoperazine treatment necessitates careful consideration of several serious warnings.
- Patients, particularly the elderly with dementia-related psychosis, are at an increased risk of death, as detailed in the Black Box Warning; trifluoperazine is not approved for this indication.
- Neuroleptic Malignant Syndrome (NMS), a potentially fatal idiosyncratic syndrome, demands immediate discontinuation of the drug and intensive supportive therapy if suspected.
- The risk of tardive dyskinesia (TD), which can be irreversible, requires continuous monitoring for involuntary movements, and consideration of alternative treatments or dose reduction if signs emerge.
- Patients should be monitored for orthostatic hypotension, particularly at the initiation of therapy or during dose escalation, due to the risk of syncope and falls.
- Anticholinergic effects can exacerbate conditions like narrow-angle glaucoma and prostatic hypertrophy.
- Changes in glucose metabolism, including hyperglycemia and diabetes, have been reported with antipsychotic use, necessitating monitoring in susceptible individuals.
- Leukopenia, neutropenia, and agranulocytosis are rare but serious hematologic adverse reactions that require vigilance and regular blood count monitoring.
- The drug can lower the seizure threshold, necessitating caution in patients with a history of seizure disorders.
- Impaired body temperature regulation, dysphagia, and QT prolongation are also significant concerns requiring careful patient assessment and monitoring during therapy.
- Patients should be advised against operating heavy machinery due to potential sedation.
How it Works (Mechanism of Action)
Trifluoperazine is a first-generation (typical) antipsychotic belonging to the phenothiazine class, characterized by its high potency. Its primary therapeutic action in psychosis is attributed to the competitive antagonism of postsynaptic dopamine D2 receptors in the mesolimbic and mesocortical pathways of the brain. By blocking D2 receptors, trifluoperazine effectively reduces dopaminergic neurotransmission, which is believed to be overactive in psychotic states, thus alleviating positive symptoms such as hallucinations, delusions, and thought disorganization. Beyond its potent dopamine antagonism, trifluoperazine also exerts significant antagonist effects on various other receptors, contributing to its diverse pharmacological profile and side effect spectrum. These include blockade of alpha-1 adrenergic receptors, leading to orthostatic hypotension; antagonism of histamine H1 receptors, causing sedation and potentially weight gain; and blockade of muscarinic M1 cholinergic receptors, resulting in anticholinergic effects like dry mouth, blurred vision, and constipation. Its high D2 occupancy correlates with a higher propensity for extrapyramidal side effects compared to lower potency typical antipsychotics.